The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer

High-density lipoprotein (HDL) is one of the major carriers of cholesterol in the blood. It attracts particular attention because, in contrast with other lipoproteins, as many physiological functions of HDL influence the cardiovascular system in favourable ways unless HDL is modified pathologically. The functions of HDL that have recently attracted attention include anti-inflammatory and anti-oxidant activities. High anti-oxidant and anti-inflammatory activities of HDL are associated with protection from cardiovascular disease. Atheroprotective activities, as well as a functional deficiency of HDL, ultimately depend on the protein and lipid composition of HDL. Further, numerous epidemiological studies have shown a protective association between HDL-cholesterol and cognitive impairment. Oxidative stress, including lipid peroxidation, has been shown to be the mediator of the pathologic effects of numerous risk factors of Alzheimer's disease. Lifestyle interventions proven to increase HDL- cholesterol levels including "healthy" diet, regular exercise, weight control, and smoking cessation have also been shown to provide neuro-protective effects. This review will focus on current knowledge of the beneficial effects of HDL-cholesterol as it relates to cardiovascular diseases, breast and lung cancers, non-Hodgkin's lymphoma, as well as its neuroprotective potential in reducing the risk of Alzheimer's disease and dementia.

[1]  K. Yano,et al.  Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. , 1997, Annals of epidemiology.

[2]  R. Sacco,et al.  High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. , 2001, JAMA.

[3]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Assmann,et al.  Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* , 2004, Current medical research and opinion.

[5]  C. O'connor,et al.  Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. , 1998, The American journal of cardiology.

[6]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[7]  D. Rader,et al.  Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. , 2003, American journal of physiology. Endocrinology and metabolism.

[8]  J. Dickerson,et al.  Plasma lipids and prolactin in patients with breast cancer. , 1986, British Journal of Cancer.

[9]  David Gimeno,et al.  Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II Study , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[10]  W. G. Wood,et al.  Cholesterol modulates amyloid beta-peptide's membrane interactions. , 2003, Pharmacopsychiatry.

[11]  T. Muckle,et al.  HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN DIFFERENTIAL DIAGNOSIS OF SENILE DEMENTIA , 1985, The Lancet.

[12]  R. Mayeux,et al.  APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.

[13]  G. Siest,et al.  Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease☆ , 2000, Neurobiology of Aging.

[14]  P. McElduff,et al.  Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.

[15]  A. Kontush,et al.  Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer’s disease , 2001 .

[16]  P. Toth.  High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. , 2005, The American journal of cardiology.

[17]  E. Mannarino,et al.  Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. , 2002, The American journal of cardiology.

[18]  L. Tessitore,et al.  Altered pattern of lipid metabolism in patients with lung cancer. , 1992, Oncology.

[19]  R. Hiatt,et al.  Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  A. von Eckardstein,et al.  Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids* , 2001, The Journal of Biological Chemistry.

[21]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[22]  R. Wikinski,et al.  Lipoprotein alterations, abdominal fat distribution and breast cancer , 1999, Biochemistry and molecular biology international.

[23]  A. Goldberg,et al.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. , 1998, The American journal of cardiology.

[24]  M. Rotheneder,et al.  Effects of low‐ and high‐density lipoproteins on the proliferation of human breast cancer cells In vitro: Differences between hormone‐dependent and hormone‐independent cell lines , 1989, International journal of cancer.

[25]  D. Rader,et al.  New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.

[26]  G. Assmann,et al.  The Münster Heart Study (PROCAM). Results of follow-up at 8 years. , 1998, European heart journal.

[27]  W. Kannel.  Range of serum cholesterol values in the population developing coronary artery disease. , 1995, The American journal of cardiology.

[28]  T. Yaginuma,et al.  Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[29]  D. Holtzman,et al.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. , 2008, The Journal of clinical investigation.

[30]  J. Gmiński,et al.  Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. , 2000, International journal of molecular medicine.

[31]  M. Michikawa.  Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease? , 2003, Journal of neuroscience research.

[32]  H. Baloglu,et al.  Alterations of serum lipids and lipoproteins in breast cancer. , 1994, Cancer letters.

[33]  O. F. Olesen,et al.  High Density Lipoprotein Inhibits Assembly of Amyloid β-Peptides into Fibrils , 2000 .

[34]  D. Albanes,et al.  Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. , 2007, Cancer research.

[35]  Eduardo Esteve,et al.  Dyslipidemia and inflammation: an evolutionary conserved mechanism. , 2005, Clinical nutrition.

[36]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[37]  G. Zuliani,et al.  Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease , 2001, BMC geriatrics.

[38]  Hilkka Soininen,et al.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.

[39]  B. Edwards,et al.  Plasma lipid alterations in leukemia and lymphoma. , 1982, The American journal of medicine.

[40]  安井 多喜雄,et al.  α-cholesterol の臨床的意義 , 1980 .

[41]  A. von Eckardstein,et al.  HDL and arteriosclerosis: beyond reverse cholesterol transport. , 2002, Atherosclerosis.

[42]  M. Loeb,et al.  Identifying research priorities on infections in older adults: proceedings of an interdisciplinary workshop , 2001, BMC geriatrics.

[43]  Jennifer G. Robinson,et al.  Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport , 2007 .

[44]  D. Playford,et al.  Low‐density lipoprotein size, high‐density lipoprotein concentration, and endothelial dysfunction in non‐insulin‐dependent diabetes , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[45]  P. Macfarlane,et al.  Association between high‐density lipoprotein and cognitive impairment in the oldest old , 2002, Annals of neurology.

[46]  Albert Hofman,et al.  Serum lipids and hippocampal volume: The link to Alzheimer's disease? , 2005, Annals of neurology.

[47]  S. Husain,et al.  Role of lipids, lipoproteins and vitamins in women with breast cancer. , 2001, Clinical biochemistry.

[48]  M. Osame,et al.  Low Levels of Serum Apolipoprotein AI and AII in Senile Dementia , 1994, The Japanese journal of psychiatry and neurology.

[49]  P. Vallance,et al.  Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. , 2001, Journal of the American College of Cardiology.

[50]  A. Branchi,et al.  Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects , 2000, International journal of clinical & laboratory research.

[51]  W. Castelli,et al.  Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. , 1988, The Canadian journal of cardiology.

[52]  M. Leon,et al.  Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease , 2004, Neurobiology of Aging.

[53]  A. Folsom,et al.  Associations of Factor VIII and von Willebrand Factor with Age, Race, Sex, and Risk Factors for Atherosclerosis , 1993, Thrombosis and Haemostasis.

[54]  Richard Mayeux,et al.  Relation of plasma lipids to Alzheimer disease and vascular dementia. , 2004, Archives of neurology.

[55]  S.-M. Kim,et al.  Glycation impairs high-density lipoprotein function , 2000, Diabetologia.

[56]  A. Császár.  Hypertriglyceridemia, the coronary heart disease risk marker "solved". , 2005, Acta physiologica Hungarica.

[57]  E. Skinner.  High-density lipoprotein subclasses. , 1994, Current opinion in lipidology.

[58]  A. Koudinov,et al.  Essential role for cholesterol in synaptic plasticity and neuronal degeneration , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  C. Brayne,et al.  Neuropathological Findings in the Very Old: Results from the First 101 Brains of a Population‐based Longitudinal Study of Dementing Disorders , 2000, Annals of the New York Academy of Sciences.

[60]  J. Després,et al.  Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease , 2012, Drugs.

[61]  M. L. Knapp,et al.  Alterations of serum lipids in breast cancer: effects of disease activity, treatment, and hormonal factors. , 1991, Clinical chemistry.

[62]  ジャーナルAMA日本版刊行会,et al.  The Journal of the American Medical Association. , 1983, JAMA.

[63]  A. Folsom,et al.  HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. , 2008, Lung cancer.

[64]  M. Hersberger,et al.  Current understanding of the metabolism and biological actions of HDL , 2005, Current opinion in clinical nutrition and metabolic care.

[65]  Sterling C. Johnson,et al.  The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study , 2005, BMC neurology.

[66]  D. Gospodarowicz,et al.  High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium. , 1982, Cancer research.

[67]  T. Meade,et al.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.

[68]  L. Bernstein,et al.  Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. , 2004, Journal of the National Cancer Institute.

[69]  E. B. Larson,et al.  Serum cholesterol and risk of Alzheimer disease , 2005, Neurology.

[70]  R. Lipton,et al.  A genotype of exceptional longevity is associated with preservation of cognitive function , 2006, Neurology.

[71]  Arthur F Kramer,et al.  Exercise, cognition, and the aging brain. , 2006, Journal of applied physiology.

[72]  E. Barrett-Connor,et al.  Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. , 1997, Circulation.

[73]  P. Whitehouse,et al.  Dementia drug development: use of information systems to harmonize global drug development. , 1997, Psychopharmacology bulletin.

[74]  K. Watson,et al.  High-density lipoprotein function recent advances. , 2005, Journal of the American College of Cardiology.

[75]  J. Mckenney,et al.  A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. , 1998, The American journal of medicine.

[76]  A. Gotto.  Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease: A Working Group Report , 2001, Circulation.

[77]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[78]  R. Hayes,et al.  Prediagnostic Total and High-Density Lipoprotein Cholesterol and Risk of Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[79]  J. Albers,et al.  Isolation and Characterization of Human Plasma Lipid Transfer Proteins , 1984, Arteriosclerosis.

[80]  P. Barter,et al.  High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. , 2003, Atherosclerosis.

[81]  Allen J. Taylor,et al.  The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.

[82]  M. Katan.  Low HDL cholesterol levels. , 2006, The New England journal of medicine.

[83]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[84]  V. Cabana,et al.  The acute‐phase response and associated lipoprotein abnormalities accompanying lymphoma , 1993, Journal of internal medicine.

[85]  W. Willett,et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.

[86]  A. Tall.  An overview of reverse cholesterol transport. , 1994, European heart journal.

[87]  D. Waters,et al.  Circadian patterns in coronary disease: the mournfulness of morning. , 1988, The Canadian journal of cardiology.

[88]  S. Umeki,et al.  Decreases in serum cholesterol levels in advanced lung cancer. , 1993, Respiration; international review of thoracic diseases.

[89]  H. Drexel.  Reducing risk by raising HDL-cholesterol: the evidence , 2006 .

[90]  N. Boyd,et al.  Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. , 1990, Journal of the National Cancer Institute.

[91]  G. Assmann,et al.  The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. , 1997, Circulation.

[92]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[93]  G. Assmann,et al.  High Density Lipoproteins Induce Cell Cycle Entry in Vascular Smooth Muscle Cells Via Mitogen Activated Protein Kinasedependent Pathway , 2001 .

[94]  M. Tabaton,et al.  Frontiers in Aging Neuroscience Aging Neuroscience Review Article Aβ and Oxidative Stress Oxidative Stress in Ad and Aging Oxidative Stress in Ad and Hypoxia Oxidative Stress in Ad and Hyperglycemia , 2022 .

[95]  Skinner Er.  High-density lipoprotein subclasses. , 1994 .

[96]  J. Saczynski,et al.  The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. , 2007, American journal of epidemiology.

[97]  A. von Eckardstein,et al.  High Density Lipoproteins Induce Cell Cycle Entry in Vascular Smooth Muscle Cells Via Mitogen Activated Protein Kinase-dependent Pathway , 2001, Thrombosis and Haemostasis.

[98]  W. Frishman.  Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialKeech A, and the FIELD study investigators (Univ of Sydney, Australia; et al) Lancet 366:1849–1861, 2005§ , 2007 .

[99]  J. Medalie,et al.  Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[100]  R. Martins,et al.  Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.

[101]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[102]  G. Engholm,et al.  Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women , 1992, Cancer Causes & Control.

[103]  A. Égerházi,et al.  Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia , 2002, European Archives of Psychiatry and Clinical Neuroscience.

[104]  J. Hardy,et al.  Amyloid at the blood vessel wall , 2006, Nature Medicine.

[105]  F. Ruschitzka,et al.  HDL and inflammation in atherosclerosis. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.

[106]  D. Haskard,et al.  Elevation of Plasma High-Density Lipoprotein Concentration Reduces Interleukin-1–Induced Expression of E-Selectin in an In Vivo Model of Acute Inflammation , 2001, Circulation.

[107]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[108]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[109]  Shuiping Zhao,et al.  Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. , 2000, Atherosclerosis.

[110]  S. Reddy,et al.  The double jeopardy of HDL , 2005, Annals of medicine.

[111]  E. Engels.  Inflammation in the development of lung cancer: epidemiological evidence , 2008, Expert review of anticancer therapy.

[112]  P. Urdal,et al.  Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women , 1994, Cancer Causes & Control.